BioAtla (BCAB) has a debt-to-equity ratio of -0.16, below the Healthcare sector average of 0.34.
Get informed when a big investor buys or sells
+ Follow-0.16
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
As of the most recent data, BCAB shows a debt-to-equity ratio of -0.16. That is below the Healthcare sector average of 0.34. Scroll down for historical charts and peer comparison views.
The Healthcare sector average debt-to-equity ratio is about 0.34. BioAtla is at -0.16, which is lower that average. That is roughly 147.8% below the sector mean. Use the comparison chart on this page to see how BCAB stacks up against individual peers as well.
Investors watch BCAB's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. BioAtla's latest reading is -0.16. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this debt-to-equity ratio page, Stockcircle has BioAtla's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently -0.16) with ownership activity and broader fundamentals.
The Healthcare average debt-to-equity ratio is about 0.34, while BCAB is at -0.16. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.